This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
AVEO Oncology Plunges on Delay in Filing Fotivda NDA With FDA
by Zacks Equity Research
AVEO Oncology (AVEO) decides against filing NDA for Fotivda on recommendation of the FDA. The agency remains concerned with the overall survival data.
Lilly (LLY) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Lilly (LLY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Top Ranked Income Stocks to Buy for February 1st
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, February 1st
Celgene (CELG) Q4 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Celgene (CELG) Q4 earnings beat estimates on robust revenues, driven by strong sales of Otezla and Revlimid.
Allergan (AGN) Q4 Earnings Beat Estimates, 2019 View Tepid
by Zacks Equity Research
Allergan (AGN) beats fourth-quarter estimates for earnings and sales with Botox being the primary sales driver. The company provides full-year guidance for 2019.
Allergan (AGN) Q4 Earnings Beat Estimates, 2019 View Tepid
by Zacks Equity Research
Allergan (AGN) beats fourth-quarter estimates for earnings and sales with Botox being the primary sales driver. The company provides full-year guidance for 2019.
Is a Beat in the Cards for Celgene (CELG) in Q4 Earnings?
by Zacks Equity Research
Investors are looking forward to Revlimid's performance and updates from the recently announced merger agreement when Celgene Corporation (CELG) reports Q4 results.
Bristol-Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Bristol-Myers Squibb (BMY) closed the most recent trading day at $48.33, moving -1.23% from the previous trading session.
Inovio's Early/Mid-Stage Vaccine Pipeline Exhibits Growth
by Zacks Equity Research
Inovio (INO) focuses on developing its most advanced candidate, VGX-3100 vaccine, which has been advancing well. Reliance on partners for funds to develop its pipeline candidates is a concern.
Drug/Biotech Stock Earnings on Jan 29: PFE, AMGN, BIIB & AGN
by Zacks Equity Research
Four drug/biotech stocks are scheduled to release their fourth-quarter results on Jan 29. Let's take a look at how these companies are poised ahead of their earnings release.
The Zacks Analyst Blog Highlights: J&J, Bristol-Myers, Lilly, AbbVie and Merck
by Zacks Equity Research
The Zacks Analyst Blog Highlights: J&J, Bristol-Myers, Lilly, AbbVie and Merck
Pharma Stock Roundup: JNJ & BMY's Q4 Earnings, Study Failures at LLY & ABBV
by Zacks Equity Research
J&J (JNJ) and Bristol-Myers (BMY) kick off earnings for pharma sector. Lilly (LLY) and AbbVie (ABBV) announce failure of late-stage studies.
Are You Looking for a High-Growth Dividend Stock? Bristol-Myers Squibb (BMY) Could Be a Great Choice
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Bristol-Myers Squibb (BMY) have what it takes? Let's find out.
What's Behind the Biotech ETF Rally to Start 2019?
by Sanghamitra Saha
Biotech ETFs have been riding on the wave of mergers and acquisitions as well as drug approvals.
Bristol-Myers (BMY) Beats Q4 Earnings, Withdraws Opdivo sBLA
by Zacks Equity Research
Bristol-Myers (BMY) beats earnings estimates in the fourth quarter but misses sales expectation by a slight margin. Eliquis and Opdivo continue to record solid sales.
5 Best Biotech Bets Likely to Outperform Estimates in Q4
by Zacks Equity Research
Let us take a look at five promising biotech stocks for the fourth quarter of 2018.
Blue Chips IBM and Proctor and Gamble Rally on Earnings
by David Borun
Investors are delighted with improved guidance as well as solid earnings
What's in Store for Bristol-Myers (BMY) in Q4 Earnings?
by Zacks Equity Research
Performance of Opdivo and the recently announced acquisition of Celgene Corporation will be key areas of focus for the investors when Bristol-Myers (BMY) reports fourth-quarter results.
Pharma Stock Roundup: Regulatory Updates in Focus at PFE, BMY, RHHBY, SNY
by Zacks Equity Research
Pfizer's (PFE) tafamidis application gets FDA's priority review. Regulatory updates for Roche's (RHHBY) and Bristol-Myers'(BMY) cancer combination drugs in focus.
Roche's sBLA for Tecentriq-Abraxane Combo Accepted by FDA
by Zacks Equity Research
Roche's (RHHBY) sBLA for the label expansion of Tecentriq in combination with Abraxane for the initial treatment of NSCLC has been accepted by the FDA.
Ligand (LGND) Takes a Hit on Citron's Negative Research Report
by Zacks Equity Research
Ligand (LGND) plunges as short-seller Citron Research questions the company's business prospects.
Bristol-Myers Squibb (BMY) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Bristol-Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights: Procter & Gamble, NVIDIA, Bristol-Myers, Deere and Ecolab
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Procter & Gamble, NVIDIA, Bristol-Myers, Deere and Ecolab
Top Analyst Reports for Procter & Gamble, NVIDIA & Bristol-Myers
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Procter & Gamble (PG), NVIDIA (NVDA) and Bristol-Myers (BMY).
Bristol-Myers' Drug Combination Gets EU Nod for Renal Cancer
by Zacks Equity Research
Bristol-Myers (BMY) gets EU approval for the immuno-oncology combination of Opdivo and low-dose Yervoy for the first-line treatment of patients with intermediate- and poor-risk advanced RCC.